Palbociclib, a kinase inhibitor for oral administration, is typically supplied as dosage strength of 125 mg, 100 mg, or 75 mg. The recommended dose for HR+/HER2− MBC is 125 mg of palbociclib once a day. The palbociclib 125 mg is the first CDK 4/6 inhibitor approved by the US FDA in conjunction with letrozole or faslodex (estrogen receptor down regulator) for metastatic (advanced) ER +Ve, breast cancer. The combination of these agents has demonstrated substantial enhancement in progression-free survival (PFS). The side effects due to palbociclib tablets are very manageable. Have to take tablets orally once a day with food for 3 consecutive weeks followed by the 1 week off treatment to comprise a full cycle of 28 days. To know the price of Palbociclib tablets in India, and other places, dial our TOLL-FREE Number: 1800-889-1064 or Email us at info@theindianpharma.com.
0
